Clinical Trial Update: Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a growth factor to prevent oral mucositis in patients with hematologic cancers. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma and Plasma Cell Neoplasm

Drugs mentioned

• Palifermin (palifermin)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Drug/Agent Toxicity by Tissue/Organ, Leukemia | Phase 2 | Status: COMPLETED